In 2022, the World Health Assembly set a target of 100% of people with type 1 diabetes having access to affordable insulin and blood glucose self-monitoring. Human insulin (regular and NPH) has been on the World Health Organization (WHO) List of Essential Medicines (EML) for decades. Glargine, a long-acting analogue insulin, was included in the EML in 2021. Previous studies have consistently shown analogue insulins are high priced, and unaffordable for those on low wages. So, between 10 March and 20 April 2023, the Addressing the Challenges and Constraint of Insulin Sources and Supply (ACCISS) Study took a global snapshot of the prices people currently pay for glargine insulin and its affordability.
Read the results here:
Guardian Article: Insulin costs almost a months wages in poorer countries